Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | The role of antibody-based therapies in MDS treatment

Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, discusses the role of antibody-based therapies in treating patients with myelodysplastic syndromes (MDS). Dr Brunner highlights the monoclonal antibodies magrolimab and sabatolimab, which are currently being evaluated in Phase III studies. Dr Brunner further suggests lenses for interpreting the data emerging from these studies and ways to apply this information for the maximum benefit in patients with high-risk MDS. This interview took place at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript (edited for clarity)

Piggybacking a little bit on how we’re using the immune system to try to target MDS. I’ll be talking a little about how we’re using antibody-based therapies in MDS and there’s a lot of ways that you can employ antibodies, but essentially they’re meant to break up the interaction between MDS cells and other cells in the microenvironment. So whether that’s through naked antibodies, through antibody drug conjugates, through bispecific antibodies and some can be targeted toward the MDS cells, some can be targeted to the immune system...

Piggybacking a little bit on how we’re using the immune system to try to target MDS. I’ll be talking a little about how we’re using antibody-based therapies in MDS and there’s a lot of ways that you can employ antibodies, but essentially they’re meant to break up the interaction between MDS cells and other cells in the microenvironment. So whether that’s through naked antibodies, through antibody drug conjugates, through bispecific antibodies and some can be targeted toward the MDS cells, some can be targeted to the immune system. There’s a lot of ways that you can use them in practice. I’ll be talking mostly about trials and looking at antibodies against CD47 and against TIM3. Magrolimab and sabatolimab are the latest in development, both are in Phase III study right now. I’ll be providing some updates on trying to understand what the role might be for antibody-based therapies. Would we expect them to actually improve upon a response rate? Or would they have more of a role on maintaining a response, more of a role in the immune system, perhaps preventing progression. How we can look at the data that comes out of these trials through those lenses to try to identify patients that are going to benefit most from any given therapy. Our hope is that we have new therapies improved for MDS, especially higher risk disease where there’s really pretty dismal outcomes still. So being smart about how we think about our trials and how we also interpret the results may give us a better way to provide a benefit to our patients.

Read more...

Disclosures

Janssen: Research Funding; Celgene/BMS: Consultancy, Research Funding; Agios: Honoraria; AstraZeneca: Research Funding; Acceleron: Honoraria; GSK: Research Funding; Keros Therapeutics: Consultancy; Novartis: Consultancy, Research Funding; Taiho: Consultancy; Takeda: Consultancy, Research Funding; Aprea: Research Funding.